Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Third Circuit Court Rejects Novo Nordisk Challenge to Inflation Reduction Act

Summary by Pharmaceutical Commerce
The appellate court upheld Medicare’s authority to negotiate lower drug prices under the Inflation Reduction Act, following similar rulings against AstraZeneca, Bristol Myers Squibb, and Novartis.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Pharmaceutical CommercePharmaceutical Commerce

Third Circuit Court Rejects Novo Nordisk Challenge to Inflation Reduction Act

The appellate court upheld Medicare’s authority to negotiate lower drug prices under the Inflation Reduction Act, following similar rulings against AstraZeneca, Bristol Myers Squibb, and Novartis.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmaceutical Commerce broke the news in on Saturday, October 11, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Inflation Reduction Act icon

Inflation Reduction Act

Drug Prices icon

Drug Prices

Medicare icon

Medicare

United States icon

United States

News
For You
SearchBlindspotLocal